Biorasi, a full-service CRO powered by ProAct+, announced the formation of an endocrinology division established to consolidate and expand Biorasi market leadership in running clinical trials in diabetes and women’s health, amongst others. The new division will be led by Bill Doyle, the division manager, out of the Miami, Florida Headquarters.
“We are pleased to culminate our decade long leadership in women’s health and diabetes clinical development with the formation of our endocrinology division,” says Dr. Boris Reznik, chairman of Biorasi. “Our global team of industry experts powered by ProAct+ delivers clinical research optimised to leading pharmaceutical, biotech and medical device companies; we look forward to expanding our business with current and prospective customers.”
“Our explosive growth in men’s and women’s health, as well as in diabetes and other endocrinology indications has driven the decision to carve out a dedicated division, “ says Bill Doyle, endocrinology division manager. “Just in the last six weeks, three major endocrinology milestones achieved include: A program we managed gained FDA approval of the Estradiol Transdermal System USP, also, we submitted the final study report for a novel type II diabetes therapy and we locked the database for a pivotal study in hormone replacement therapy for postmenopausal women.”